Home
Live Updates
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinsons disease : comparemela.com
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease
CAMBRIDGE - Sage Therapeutics, Inc. announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor in people with...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Ashley Kaplowitz ,
Barry Greene ,
Matthew Henson ,
Nasdaq ,
Sage Therapeutics Inc ,
Wechsler Adult Intelligence Scale Fourth ,
Coding Test ,
Chief Executive Officer ,
Private Securities Litigation Reform Act ,
News Publishing ,
comparemela.com © 2020. All Rights Reserved.